Literature DB >> 3481326

Diffusion of ofloxacin into human lung tissue.

L Couraud1, J B Fourtillan, M C Saux, A Bryskier, M Vincent du Laurier.   

Abstract

Ofloxacin 200mg twice daily was administered to 17 patients with pulmonary disorders, which necessitated surgery, during the preceding 48 hours and 200mg was administered 1 hour before the operation. During surgery, blood samples and specimens of healthy and diseased lung tissues were taken simultaneously. Ofloxacin levels were determined by HPLC. The mean values of the tissue concentration/plasma concentration ratio were 3.5 +/- 0.4 for the healthy tissue and 3.9 +/- 0.4 for the diseased tissue. These values reflected good penetration of ofloxacin into both healthy and atelectasic pulmonary parenchyma.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3481326     DOI: 10.2165/00003495-198700341-00009

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  6 in total

1.  [Multicenter study of ofloxacin activity on bacteria isolated from a hospital environment].

Authors:  C J Soussy; J Le Van Thoi; J Duval; C Morel; B Malbruny; J F Acar; M D Kitzis; M Mounier; F Denis; P Courvalin
Journal:  Pathol Biol (Paris)       Date:  1986-05

2.  Comparison of the antibacterial in vitro and in vivo activity of ofloxacin (HOE 280 DL 8280) and nalidixic acid analogues.

Authors:  G Seibert; M Limbert; N Klesel
Journal:  Eur J Clin Microbiol       Date:  1983-12       Impact factor: 3.267

3.  [Respiratory tract infections--clinical results with ofloxacin].

Authors:  P M Shah; H Knothe
Journal:  Infection       Date:  1986       Impact factor: 3.553

4.  [Effect ofloxacin on Haemophilus influenza, Streptococcus pneumoniae and Neisseria meningitidis. Comparison with similar molecules].

Authors:  H Dabernat; C Delmas; M B Lareng
Journal:  Pathol Biol (Paris)       Date:  1985-05

5.  [New oral quinolone compounds in chronic bronchitis].

Authors:  B I Davies; F P Maesen; J P Teengs; C Baur
Journal:  Infection       Date:  1986       Impact factor: 3.553

6.  The pharmacokinetics and tissue penetration of ofloxacin.

Authors:  M R Lockley; R Wise; J Dent
Journal:  J Antimicrob Chemother       Date:  1984-12       Impact factor: 5.790

  6 in total
  8 in total

1.  Penetration of orally administered prulifloxacin into human lung tissue.

Authors:  Ercole Concia; Benedetta Allegranzi; Giovanni B Ciottoli; Giovanna Orticelli; Marcello Marchetti; Paolo Dionisio
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 2.  Ofloxacin. A reappraisal of its antimicrobial activity, pharmacology and therapeutic use.

Authors:  P A Todd; D Faulds
Journal:  Drugs       Date:  1991-11       Impact factor: 9.546

Review 3.  Ofloxacin clinical pharmacokinetics.

Authors:  K C Lamp; E M Bailey; M J Rybak
Journal:  Clin Pharmacokinet       Date:  1992-01       Impact factor: 6.447

4.  Intraoperative concentrations of ofloxacin in serum, bile fluid, and gallbladder wall tissue.

Authors:  A Chin; M P Okamoto; M A Gill; D A Sclar; T V Berne; A E Yellin; P N Heseltine; M D Appleman
Journal:  Antimicrob Agents Chemother       Date:  1990-12       Impact factor: 5.191

Review 5.  Fluoroquinolone antibiotics. Microbiology, pharmacokinetics and clinical use.

Authors:  J H Paton; D S Reeves
Journal:  Drugs       Date:  1988-08       Impact factor: 9.546

6.  Penetration of ofloxacin into human lung tissue following a single oral dose of 200 milligrams.

Authors:  F Serour; M Dan; A Gorea; A Yellin; Y Lieberman; S A Berger
Journal:  Antimicrob Agents Chemother       Date:  1991-02       Impact factor: 5.191

Review 7.  Quinolones in the treatment of lower respiratory tract infections caused by intracellular pathogens.

Authors:  C Chidiac; Y Mouton
Journal:  Infection       Date:  1991       Impact factor: 3.553

8.  Ofloxacin penetration into tuberculous pleural effusion.

Authors:  W W Yew; J Lee; C Y Chan; S W Cheung; P C Wong; S Y Kwan
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.